ArticleBMC microbiology2026
Co-occurrence of bla
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) is a growing threat to public health, especially in low- and middle-income countries. This study aimed to identify multidrug-resistant (MDR) pathogens in clinical samples from a tertiary hospital in Ecuador, evaluate their phenotypic antibiotic susceptibility, and compare these findings with genotypic resistance patterns.
methodsClinical samples were collected from an Ecuadorian reference hospital from September 2022 to September 2023. Bacterial identification and susceptibility testing were performed using the VITEK-2 system. After genomic DNA extraction, key resistance genes (blaKPC, blaNDM, blaVIM, blaOXA−48, blaCTX−M and blaIMP−1) were identified via multiplex PCR with TaqMan probes. Phenotypic and genotypic data were integrated using bioinformatics tools.
resultsThe 216 bacterial isolates analyzed exhibited resistance phenotypes, primarily to carbapenems and third-generation cephalosporins. Klebsiella pneumoniae was the most prevalent resistant species (59.7%), followed by Pseudomonas aeruginosa (11.6%) and Serratia marcescens (8.3%). However, 20.8% of the isolates phenotypically resistant to carbapenems did not carry any of the targeted carbapenemase genes. The blaKPC gene was most common (70.8%), followed by blaNDM (9.7%) and blaVIM (2.8%). Ten isolates harbored gene combinations, including, to our knowledge, the first reported co-occurrence of blaKPC and blaOXA−48 in K. pneumoniae in Ecuador.Neither blaIMP−1 nor blaCTX−M was detected in any of the evaluated isolates.
conclusionsThere is strong concordance between carbapenemase genes and the MDR phenotype, some of which are newly reported in Ecuador. However, the absence of gene detection in some resistant isolates suggests the presence of alternative resistance mechanisms. Integrating phenotypic and molecular methods that target locally prevalent resistance genes improves the accuracy of AMR detection and supports better diagnosis and infection control in hospital settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.